Company intelligence / Profile preview

LinkBIO

Ownership: Private
Development stage: Other

Overview

LinkBIO is pioneering bispecific DNA aptamer drugs for rare hematologic diseases using its proprietary MACE®‑SELEX platform. The company has established multiple academic and industry collaborations, received a patent grant in South Korea, and was selected by the Japan Agency for Medical Research and Development for a major project. Clinical results are not yet available as programs are pre-clinical.

Therapeutic areas: Hematology
Modalities: DNA aptamerBispecific DNA aptamerNucleic acid therapeutics
Industry: Biotech

Partnerships

University of TokyoNara Medical UniversityKanematsu Chemicals CorporationFunakoshi CompanyKyushu University/Professor Tomo Hoshino’s Laboratory

Beyond the preview

Go deeper on LinkBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LinkBIO.